COMMUNIQUÉS West-GlobeNewswire

Safety Shot Provides Further Details on Strategic Board Refresh and Corporate Vision
18/09/2025
Company to Seek Shareholder Approval for New Director Appointments SCOTTSDALE, AZ, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Following its announcement yesterday regarding a strategic refresh of its Board of Directors, Safety [...]
First Insight Launches MaximEyes AI, Powered by EVAA
18/09/2025
New AI suite automates front- and back-office workflows, giving eye care practices more time for patients PORTLAND, Ore., Sept. 18, 2025 (GLOBE NEWSWIRE) -- First Insight, a leader in eye care EHR and practice [...]
Replimune Provides Update Following Type A Meeting with FDA
18/09/2025
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the [...]
BioCardia Announces Pricing of Up To $12 Million Public Offering
18/09/2025
$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [ [...]
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
18/09/2025
Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc [...]
Senti Bio to Present at the MedInvest Biotech & Pharma Conference
18/09/2025
Live webcast presentation on Wednesday, September 24th at 9:55 AM PT SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology [...]
After Transforming Neuro Care, Sevaro Secures $39M to Expand AI-Powered Specialty Care Platform
18/09/2025
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Sevaro Health, the company transforming neurological care in the United States, today announced the close of a $39 million oversubscribed Series B funding round . The round [...]
Dark Horse Consulting Group Acquires Converge Consulting
18/09/2025
WALNUT CREEK, Calif. and CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational consulting in advanced therapies—specifically the [...]
OrganOx metra® Receives FDA Approval for Operation During Air Transport, Expanding Access to Life-Saving Liver Perfusion Technology
18/09/2025
Partnership with Strata Critical Medical (NASDAQ:SRTA) enables 24/7, device-to-donor support across the U.S. OrganOx Ltd., the organ technology company tackling the world's toughest transplant challenges, announced that [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2025
18/09/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2025 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les [...]
KFSHRC to Participate in C3 Davos of Healthcare™ Japan Summit
18/09/2025
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has announced its participation in the C3 Davos of Healthcare™ Japan Summit, taking place on September 24, 2025 [...]
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
18/09/2025
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the [...]
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
18/09/2025
- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained [...]
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
18/09/2025
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today [...]
Cullgen Completes Enrollment in Phase 1 Trial of its Novel Non-Opioid Pain Product Candidate CG001419
18/09/2025
- Cullgen anticipates filing an IND and starting phase 2 clinical trials in early 2026 for this candidate which is part of a new class of pain signaling channel modulators - SAN DIEGO, Sept. 18, 2025 (GLOBE NEWSWIRE [...]
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
18/09/2025
Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD) Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc [...]
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
18/09/2025
Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage [...]
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
18/09/2025
Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE [...]
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
18/09/2025
Completed patient enrollment within nine months with nearly half enrolled from the U.S. Expect to report Phase 3 topline data in the first half of 2026 On track to submit BLA in the second half of 2026 for an [...]

Pages